Hjem › Alpha-1-antitrypsinmangel › Californien
Alpha-1-antitrypsinmangel kliniske forsøg i Californien
4 studier for Alpha-1-antitrypsinmangel søger deltagere på steder i Californien.
Byer i Californien
Officiel studietekst (engelsk)
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 100, Los Angelas
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 11. aug. 2026 · NCT07555483Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
- University of California San Diego, Altman Clinical and Translational Institute, La Jolla
- UCLA Pulmonary and Critical Care, Los Angeles
- Stanford University, Palo Alto
- og 1 flere
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 13. maj 2026 · NCT05677971Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
- University of California San Diego, La Jolla
- UCLA Pulmonary and Critical Care, Los Angeles
- University of California Benioff Children's Hospital, San Francisco
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 5. mar. 2026 · NCT06165341PiMZ Longitudinal Cohort (PiMZ Logic)
- University of California- Los Angeles, Los Angeles
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 16. jan. 2026 · NCT06505603Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.